Immix Biopharma reports 95% complete response rate in NEXICART-2 trial

Immix announced interim results from its NEXICART-2 Phase 2 trial showing a 95% complete response rate (19 of 20 patients) in relapsed/refractory AL Amyloidosis patients treated with NXC-201, with all CRs achieved within one year and no relapses observed. The company plans to initiate a Phase 3 trial in newly diagnosed patients and expects BLA submission by end of March 2027, potentially expanding addressable market in the $6 billion amyloidosis therapeutic space.